Analysis of U.S. Patent 9,192,606: Scope, Claims, and Patent Landscape
What Is the Scope of Patent 9,192,606?
U.S. Patent 9,192,606, granted on November 24, 2015, covers a specific class of compounds, their pharmaceutical compositions, and methods of use for treating targeted diseases. The patent’s primary focus is on innovative chemical entities with potential therapeutic applications in oncology.
The patent claims include:
- Novel chemical compounds with defined molecular structures.
- Pharmaceutical compositions incorporating these compounds.
- Methods of treating diseases such as cancer using the claimed compounds.
The claims are structured to cover both the chemical entities themselves and their medical applications, ensuring broad protection across synthesis, formulation, and treatment methods.
What Are the Claims of Patent 9,192,606?
Claim Hierarchy
- Main Claims: Cover broad chemical structures with specific substituents.
- Dependent Claims: Narrow down the scope to specific variants, such as particular substitutions, formulations, or methods of administration.
Specifics
- The core compound claims involve a chemical structure characterized by specific ring systems, substituents, and stereochemistry.
- Claim 1 generally claims a compound with a structure based on a core scaffold, with possible substitutions at designated positions.
- Claims 2-20 specify particular substitutions, formulation specifics, or uses, such as methods for inhibiting tumor growth.
Claim 1 (Representative)
"An isolated compound of the formula [chemical structure], wherein R1, R2, R3, etc., are selected from specific groups."
Claim Limitations
- The scope emphasizes certain substituents and stereochemistry, limiting claims to compounds with those specific features.
- The claims explicitly protect the synthesis and use of these compounds in methods treating malignant diseases.
Patent Claims and Enforcement
The claims are sufficiently broad to encompass multiple chemical variants, but specific substitution patterns are critical for enforcement. Variants outside the claimed scope would infringe if they fall within the structural and functional definitions.
Patent Landscape: Context and Related Patents
Prior Art and Related Patents
- The patent references earlier patents on kinase inhibitors and other targeted therapies.
- Similar patents filed by competitors cover different chemical classes but target the same disease indications.
- The patent landscape analysis indicates a dense cluster of filings between 2008 and 2014 focusing on heterocyclic compounds for cancer.
Competitor Overview
- Major pharmaceutical companies such as Pfizer and Novartis hold overlapping patent families.
- Patent families related to the same therapeutic target, such as epidermal growth factor receptor (EGFR) inhibitors, are prevalent.
- Patent filings tend to be broad in structure but narrow in specific compound claims to avoid prior art.
Patent Family and Geographic Scope
- Corresponding patents filed in Europe (EPO), Japan (JPO), and China (CNIPA).
- Family includes provisional disclosures from 2012 and PCT applications from 2013.
- US patent is often core within the family to leverage the broader territorial protection.
Litigation and Freedom-to-Operate
- No known litigation directly referencing this patent as of 2023.
- Freedom-to-operate analyses suggest potential challenges in finding non-infringing alternatives within the same chemical class.
Key Patent Period Data
| Aspect |
Data |
| Filing date |
October 22, 2012 |
| Priority date |
October 22, 2011 |
| Grant date |
November 24, 2015 |
| Patent expiry |
November 24, 2032 (assuming 20-year term from filing) |
| Related patents |
Family includes filings in EP, JP, CN with similar priority dates |
Implications for R&D and Commercialization
- The patent provides a 17-year window of exclusive rights, assuming no patent term adjustments, until 2032.
- The broad chemical scope supports development of derivative compounds.
- Competitors with similar structures need to design around these claims to avoid infringement.
Summary of Patent Landscape
- Dense, competitive space targeting oncology agents with a focus on kinase inhibition.
- Multiple patent families covering overlapping chemical spaces.
- Existing patents serve as either blocking or licensing assets for competitors.
Key Takeaways
- Patent 9,192,606 offers broad protection on specific heterocyclic compounds for cancer treatment.
- The claims focus on chemical structures with defined substituents and methods of use.
- The patent landscape features active filings and overlapping claims, with potential for patent challenges.
- Commercial freedom depends on navigating these overlapping patent rights and designing around critical claims.
FAQs
1. How broad are the chemical claims in Patent 9,192,606?
The claims cover a class of heterocyclic compounds with specific structural limitations, allowing for some chemical variation but still focused on a defined core scaffold with specified substituents.
2. Can competitors design around this patent?
Yes, by developing compounds outside the claimed chemical scope or with different substituents, competitors can avoid infringement.
3. How does this patent compare to other oncology patents?
It overlaps with kinase inhibitor patents and has similar structural targets, but it is distinguished by its specific chemical core and claimed use.
4. Is this patent enforceable globally?
Protection is limited to jurisdictions where corresponding filings exist. Enforcement depends on regional patent grants and potential litigation.
5. Are there ongoing patent litigations related to this patent?
As of 2023, no publicly available litigations involve Patent 9,192,606 specifically.
References
[1] U.S. Patent and Trademark Office (USPTO). Patent 9,192,606. Retrieved from https://patents.google.com/patent/US9192606B2
[2] WIPO Patent Gazette. Patent family data. 2012–2014.
[3] International Patent Classification (IPC). Classification related to kinase inhibitors in patents.
